[go: up one dir, main page]

MX2018007681A - Composicion farmaceutica osmotica oral de vildagliptin. - Google Patents

Composicion farmaceutica osmotica oral de vildagliptin.

Info

Publication number
MX2018007681A
MX2018007681A MX2018007681A MX2018007681A MX2018007681A MX 2018007681 A MX2018007681 A MX 2018007681A MX 2018007681 A MX2018007681 A MX 2018007681A MX 2018007681 A MX2018007681 A MX 2018007681A MX 2018007681 A MX2018007681 A MX 2018007681A
Authority
MX
Mexico
Prior art keywords
vildagliptin
pharmaceutical composition
salt
surrounding
osmotic pharmaceutical
Prior art date
Application number
MX2018007681A
Other languages
English (en)
Inventor
Madhukar Kodgule Mandar
Bansal Amit
Sangle Ganesh
Swain Kapileshwar
Saigal Nitin
Gaikwad Sanjay
Kumar Agarwal Sunil
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of MX2018007681A publication Critical patent/MX2018007681A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona una composición farmacéutica osmótica que comprende: (a) un núcleo, que comprende: (i) una capa de fármaco que comprende Vildagliptin o una sal del mismo, y uno o más excipientes farmacéuticamente aceptables; (ii) una capa expulsora (por presión osmótica) que comprende óxido de polietileno que tiene un peso molecular de aproximadamente 5,000,000 a aproximadamente 8,000,000, en donde la relación en peso de Vildagliptin o una sal del mismo y óxido de polietileno varía de aproximadamente 1:1 a aproximadamente 1:5; (b) un recubrimiento de sello que circunda el núcleo; (c) un recubrimiento de liberación sostenida que comprende acetato de celulosa que circunda el recubrimiento de sello; (d) una capa de fármaco de liberación inmediata que comprende Vildagliptin o una sal del mismo que circunda al recubrimiento de liberación sostenida. También se proporciona un proceso para preparar estas composiciones.
MX2018007681A 2015-12-28 2016-12-23 Composicion farmaceutica osmotica oral de vildagliptin. MX2018007681A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4891MU2015 2015-12-28
PCT/IB2016/057975 WO2017115252A1 (en) 2015-12-28 2016-12-23 An oral osmotic pharmaceutical composition of vildagliptin

Publications (1)

Publication Number Publication Date
MX2018007681A true MX2018007681A (es) 2018-11-14

Family

ID=57966046

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007681A MX2018007681A (es) 2015-12-28 2016-12-23 Composicion farmaceutica osmotica oral de vildagliptin.

Country Status (6)

Country Link
KR (1) KR20180092981A (es)
BR (1) BR112018013195A2 (es)
MX (1) MX2018007681A (es)
PH (1) PH12018550075A1 (es)
RU (1) RU2706706C1 (es)
WO (1) WO2017115252A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19616486C5 (de) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
EP1537880A4 (en) 2002-09-11 2009-07-01 Takeda Pharmaceutical Sustained release preparation
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
CA2622579C (en) 2005-09-20 2013-12-31 Novartis Ag Use of a dpp-iv inhibitor to reduce hypoglycemic events
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
JP2011513408A (ja) * 2008-03-04 2011-04-28 メルク・シャープ・エンド・ドーム・コーポレイション メトホルミン及びジペプチジルペプチダーゼ−ｉｖ阻害剤の併用医薬組成物
ES2487271T3 (es) 2011-10-06 2014-08-20 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulaciones de dosificación sólidas inhibidoras de DPP-IV
RU2015105097A (ru) 2012-08-23 2016-10-10 Кардиолинкс Аг Композиции аминоалкилнитрата с пролонгированным высвобождением

Also Published As

Publication number Publication date
BR112018013195A2 (pt) 2018-12-11
KR20180092981A (ko) 2018-08-20
PH12018550075A1 (en) 2019-01-28
RU2706706C1 (ru) 2019-11-20
WO2017115252A1 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
WO2015184127A3 (en) Stable cannabinoid formulations
WO2018165404A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
EP3590498A4 (en) PREPARATION WITH INCLUDING COMPLEX OF VARENICLINE OR PHARMACEUTICAL SAFE SALT THEREOF FOR ORAL ADMINISTRATION
CL2016002560A1 (es) Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación.
MX2017003561A (es) Composiciones y metodos para revestimientos cannabinoides para su uso en la administracion de farmacos.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
PH12017502376B1 (en) Oral solid formulation containing irinotecan and method of preparing the same
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
WO2020127819A3 (en) Pharmaceutical composition comprising apixaban
PH12016500693A1 (en) Slow-release solid oral compositions
WO2015125152A3 (en) Pharmaceutical compositions of asenapine
WO2019194773A3 (en) The combination comprising linagliptin and metformin
EP3648745A4 (en) PHARMACEUTICAL COMPOSITION WITH SPHERICAL TABLET OF MULTIPLE UNITS WITH AMEOMEPRAZOLE AND SPHERICAL PHARMACEUTICAL SALT THEREOF AND METHOD FOR MANUFACTURING THE PHARMACEUTICAL COMPOSITION
MX2021014830A (es) Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi.
MX359887B (es) Composicion masticable para administracion oral y proceso para preparar la misma.
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
WO2017064652A3 (en) Low dose oral dipyridamole compositions and uses thereof
WO2016167605A3 (ko) 고혈압 치료제를 이용한 흡연 및 비흡연자의 폐암 억제 방법
PH12018550075A1 (en) An oral osmotic pharmaceutical composition of vildagliptin
WO2018069805A3 (en) Method for preparation of liquid oral composition of l-thyroxin
CY1125762T1 (el) Νεα απο του στοματος σκευασματα βελινοστατης
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
WO2016187595A3 (en) Oral pharmaceutical composition of methylergonovine
PH12016502527A1 (en) Stabilized desmopressin